Next Article in Journal
Astrocytic Vesicle Mobility in Health and Disease
Previous Article in Journal
Melatonin Receptor Genes in Vertebrates
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2013, 14(6), 11224-11237; doi:10.3390/ijms140611224

Cisplatin Protects against Acute Liver Failure by Inhibiting Nuclear HMGB1 Release

Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan University, Wuhan 430060, China
*
Author to whom correspondence should be addressed.
Received: 4 April 2013 / Revised: 15 May 2013 / Accepted: 21 May 2013 / Published: 27 May 2013
(This article belongs to the Section Biochemistry, Molecular Biology and Biophysics)
View Full-Text   |   Download PDF [865 KB, uploaded 19 June 2014]   |  

Abstract

Cisplatin is one of the most widely used chemical drugs for anticancer treatment. Recent studies have focused on the ability of cisplatin to retain the high mobility group box 1 (HMGB1) protein in cisplatin-DNA adducts, thereby preventing its release from the nucleus. Because HMGB1 is a powerful inflammatory mediator in many diseases, the aim of this study is to evaluate the therapeutic effect of cisplatin acute liver failure. In this study, low-dose cisplatin was administered to treat PMA-induced macrophage-like cells induced by PMA and rats with acute liver failure. We found that cell viability and liver injury were greatly improved by cisplatin treatment. The extracellular levels of HMGB1, TNF-α and IFN-γ were also significantly decreased by the administration of cisplatin. During inflammation, nuclear HMGB1 translocates from the nucleus to the cytoplasm. The administration of cisplatin reduced the cytoplasmic levels of HMGB1 and increased nuclear HMGB1 levels in vitro and in vivo. In conclusion, cisplatin can protect against acute liver failure by retaining HMGB1 in the nucleus and preventing its release into the extracellular milieu.
Keywords: cisplatin; acute liver failure; high mobility group box-1; HMGB1 translocation; inflammation cisplatin; acute liver failure; high mobility group box-1; HMGB1 translocation; inflammation
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Li, X.; Wang, L.-K.; Wang, L.-W.; Han, X.-Q.; Yang, F.; Gong, Z.-J. Cisplatin Protects against Acute Liver Failure by Inhibiting Nuclear HMGB1 Release. Int. J. Mol. Sci. 2013, 14, 11224-11237.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top